CD79A and COVID-19: Although the LIPS assay could not discriminate between IgA1 and IgA2, the correlation we found concerning anti-spike IgA with a faster control of the virus suggests that they were IgA1 or that IgA1 were more abundant than IgA2 since these latter ones have been shown to elicit a neutrophil pro-inflammatory response correlated with fatal outcome in COVID-19 patients22.